MFO selling and/or shorting IS the boogeyman false
Post# of 72436
In the Modified Intention-to-Treat population, 71.4% of patients receiving placebo developed severe Oral Mucositis, compared to 25.0% of patients receiving Brilacidin [mITT Population] (p=0.048).
In the Per Protocol population, 72.7% of patients receiving placebo developed severe Oral Mucositis, compared to 14.3% of patients receiving Brilacidin [PP Population] (p=0.025).
The stark difference between how our drug performed against placebo will be a focus of our FDA meeting and provides us with a high-degree of confidence in the treatment potential and commercial value of our asset. As we have shared previously, our research shows there is a significant market opportunity for treating Oral Mucositis in Head and Neck Cancer patients receiving chemoradiation, as there currently is no FDA-approved drug. Of course, there are no assurances stated or implied regarding successfully developing a drug, but if we are successful, we believe that earnings from a new, easy-to-use OM drug could be many multiples of our present market cap. This keeps us driving forward in executing on our business model and building shareholder value.
For those that continue the false narrative FUD that the MFO is selling/shorting here is Schedule D in black and white:
Pursuant to the Purchase Agreement, the undersigned irrevocably agrees with the Company that, from the date hereof until ninety (90) days following the first closing date of the Company’s offering of registered securities pursuant to an effective shelf registration statement on Form S-3 (File No. 333-220419) and the Purchase Agreement (the “Offering”) (such period, the “Restriction Period”), the undersigned will not offer, sell, contract to sell, hypothecate, pledge or otherwise dispose of (or enter into any transaction which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic disposition due to cash settlement or otherwise) by the undersigned or any Affiliate (as defined in the Purchase Agreement) of the undersigned or any person in privity with the undersigned or any Affiliate of the undersigned), directly or indirectly, or establish or increase a put equivalent position or liquidate or decrease a call position equivalent within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), with respect to, any shares of common stock of the Company or securities convertible, exchangeable or exercisable into, shares of common stock of the Company beneficially owned, held or hereafter acquired by the undersigned (the “Securities”)
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)